logo-loader
viewAvalon GloboCare Corp

Avalon GloboCare to produce its first series of clinical-grade exosome products by end of 2019

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive Investors that the biotech company will be producing its first series of clinical grade exosome products, used for skincare and hair growth, by the second half of 2019.

Dr. Jin adds that the New Jersey-based company is collaborating with the Massachusetts Institute of Technology to develop an AI-enhanced protein design technology, which will allow the company to innovate in new cell therapy techniques.

Quick facts: Avalon GloboCare Corp

Price: 1.75 USD

NASDAQ:AVCO
Market: NASDAQ
Market Cap: $138.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avalon Globocare Corp seeing success working in the celltech space

Avalon GloboCare CEO (NASDAQ:AVCO) Dr. David Jin sat down with Proactive's Steve Darling at the 12th annual LD Micro Conference. The company is a clinical-stage CellTech bio-developer specializing in cellular therapeutics. Dr Jin talked about success in 2019 and what he expects in 2020.

on 12/10/2019

2 min read